Spots Global Cancer Trial Database for Veliparib and Topotecan for Relapsed Ovarian Cancer With Negative or Unknown BRCA Status
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Veliparib and Topotecan for Relapsed Ovarian Cancer With Negative or Unknown BRCA Status
Official Title: Veliparib (ABT888) and Topotecan (Hycamtin®) for Patients With Platinum-Resistant or Partially Platinum-Sensitive Relapse of Epithelial Ovarian Cancer With Negative or Unknown BRCA Status
Study ID: NCT01690598
Conditions
Study Description
Brief Summary: The purpose of this study is to investigate the effect of combined topotecan and veliparib (ABT888) treatment in relapsed ovarian cancer with tumor progression and negative or unknown BRCA mutation status.
Detailed Description:
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: FEMALE
Healthy Volunteers: No
Locations
Department of Oncology, Vejle Hospital, Vejle, , Denmark
Contact Details
Name: Anders Jakobsen, MD, DMSc
Affiliation: Vejle Hospital
Role: STUDY_CHAIR
Name: Hanne Kanstrup, MD
Affiliation: Vejle Hospital
Role: PRINCIPAL_INVESTIGATOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
